In conclusion, the present research has shown a potential benefit of DEX that modifies both airway inflammation and airway remodeling in a chronic asthma model through the inhibition of the TLR4/NF-κB activity, which provides a novel therapeutic strategy for asthma. This evidence concerns the gene NFKB1 and chronic asthma.